© 2003 by European Society of Cardiology
Copyright © 2003, European Society of Cardiology
De novo vasculogenesis in the heart
The Center for Transgene Technology and Gene Therapy, Flanders Interuniversitary Institute for Biotechnology, KU Leuven, Leuven B-3000, Belgium
peter.carmeliet{at}med.kuleuven.ac.be
* Corresponding author. Center for Transgene Technology and Gene Therapy, Flanders Interuniversitary Institute for Biotechnology, KU Leuven, Campus Gasthuisberg, Herestraat 49, B-3000, Leuven, Belgium. Tel.: +32-16-345-772; fax: +32-16-345-990.
The formation of the embryonic heart vasculature is a complex process and is the result of vasculogenic, angiogenic and arteriogenic mechanisms, involving cells from distinct origins. In the neonate and the adult, several sources of endothelial precursor cells (EPCs) have been identified that contribute to physiological and pathological vascularization, consistent with the concept of de novo vasculogenesis after birth, including in the heart. The existence of EPCs in the adult has offered the possibility to use these cells for revascularization of ischemic tissues. An important challenge for vascular regeneration in ischemic and post-infarction patients is now to identify the most adequate cell source and cell dose for sufficient revascularization. This review gives an overview of the cellular and molecular cues involved in the formation of the heart vasculature before and after birth and discusses some of the recent insights and outstanding questions on EPCs and other vascular progenitors—both from a biological and therapeutic perspective.
KEYWORDS Angiogenesis; Stem cells; Heart failure; Infarction; Ischemia
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
T. A. Gorr and A. Deten Manipulating myocyte cell cycle control for cardiac repair Cardiovasc Res, November 1, 2008; 80(2): 161 - 162. [Full Text] [PDF] |
||||
![]() |
V. W.M. van Hinsbergh, M. A. Engelse, and P. H.A. Quax Pericellular Proteases in Angiogenesis and Vasculogenesis Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 716 - 728. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Religa, R. Cao, M. Bjorndahl, Z. Zhou, Z. Zhu, and Y. Cao Presence of bone marrow-derived circulating progenitor endothelial cells in the newly formed lymphatic vessels Blood, December 15, 2005; 106(13): 4184 - 4190. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Wagner, K.-D. Wagner, H. Theres, C. Englert, A. Schedl, and H. Scholz Coronary vessel development requires activation of the TrkB neurotrophin receptor by the Wilms' tumor transcription factor Wt1 Genes & Dev., November 1, 2005; 19(21): 2631 - 2642. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Toyota, D. C. Warltier, T. Brock, E. Ritman, C. Kolz, P. O'Malley, P. Rocic, M. Focardi, and W. M. Chilian Vascular Endothelial Growth Factor Is Required for Coronary Collateral Growth in the Rat Circulation, October 4, 2005; 112(14): 2108 - 2113. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. B. Friedrich and M. Bohm Human umbilical cord blood cells and myocardial infarction: Novel ways to treat an old problem Cardiovasc Res, April 1, 2005; 66(1): 4 - 6. [Full Text] [PDF] |
||||
![]() |
M. Simons Angiogenesis: Where Do We Stand Now? Circulation, March 29, 2005; 111(12): 1556 - 1566. [Full Text] [PDF] |
||||
![]() |
B. H. Annex and M. Simons Growth factor-induced therapeutic angiogenesis in the heart: protein therapy Cardiovasc Res, February 15, 2005; 65(3): 649 - 655. [Abstract] [Full Text] [PDF] |
||||




